|
Video: What is a Stock Split?
|
|
Talis Biomedical is engaged in transforming diagnostic testing by developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions at the point of care. Co. is developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system comprises a compact instrument, single-use test cartridges and software that is designed to support a central cloud database, which work together and are designed to provide central laboratory levels of accuracy. Co. is developing additional tests for infections related to women's health, including a panel for sexually transmitted infections and other infections. According to our TLIS split history records, Talis Biomedical has had 1 split. | |
|
Talis Biomedical (TLIS) has 1 split in our TLIS split history database. The split for TLIS took place on July 06, 2023. This was a 1 for 15 reverse split, meaning for each 15 shares of TLIS owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 66.6666666666667 share position following the split.
When a company such as Talis Biomedical conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the TLIS split history from start to finish, an original position size of 1000 shares would have turned into 66.6666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Talis Biomedical shares, starting with a $10,000 purchase of TLIS, presented on a split-history-adjusted basis factoring in the complete TLIS split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
02/16/2021 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$367.50 |
|
End price/share: |
$9.14 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-97.51% |
|
Average Annual Total Return: |
-68.60% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$248.71 |
|
Years: |
3.19 |
|
|
|
Date |
Ratio |
07/06/2023 | 1 for 15 |
|
|